Novo Nordisk clears fresh court hurdle, shares extend buyback support

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:48.

Nuevo Nordisk A/S (DK0060534915) remains in focus on Nasdaq Copenhagen as a South African court backs the company’s effort to block Ozempic copies while a running share repurchase programme continues. The combination of legal defense and capital returns keeps the diabetes specialist firmly on analyst radar.

What Reuters and filings show

MarketScreener cites that on June 22, a South African court granted Novo Nordisk’s petition to halt copycat versions of its GLP-1 drug Ozempic, underscoring the firm’s enforcement of intellectual property in growth markets. The note references a Reuters-tagged item on the ruling, highlighting ongoing litigation around popular obesity and diabetes treatments.

On the same date, the company reported progress in its ongoing share repurchase programme, executed under board authorization, with daily share buybacks on Nasdaq Copenhagen documented in investor releases. These buybacks are part of Novo Nordisk’s capital allocation framework, which has historically combined rising ordinary dividends with systematic repurchases to manage its capital structure.

Analysts stay constructive

Consensus data compiled by MarketScreener shows multiple houses covering Novo Nordisk with a predominantly positive stance. Nordea Bank recently reiterated a Buy rating on the shares, while Berenberg lifted its price target to 325 Danish kroner and confirmed its Buy recommendation in a June 18 note, reflecting confidence in the GLP-1 franchise.

Deutsche Bank keeps a Hold rating and a 290 kroner target, pointing to valuation constraints even as fundamentals remain robust. Oddo BHF describes a “short-term opportunity” in the shares, indicating that several European brokers still see further upside potential from obesity and cardiometabolic pipelines.

The product behind the stock

Novo Nordisk generates most of its revenue from diabetes and obesity medicines, particularly GLP-1 analogues such as Ozempic for type 2 diabetes and Wegovy for obesity management. These injectable products have seen strong global demand, supported by clinical data on weight reduction and cardiovascular risk, and underpin much of the company’s medium-term growth narrative.

Where the shares trade today

As of 2026-06-23, 21:43, Novo Nordisk shares (DK0060534915) trade on Gettex at 41.55 euros, with the latest quote indicating a 3.60 percent gain on the day. On Nasdaq Copenhagen, the B shares last changed hands at around 304.60 Danish kroner, modestly higher on the session.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance.